

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 October 2006 (12.10.2006)

PCT

(10) International Publication Number
WO 2006/107745 A3

- (51) **International Patent Classification:**
A61K 49/00 (2006.01) A01N 65/00 (2009.01)
A61K 36/00 (2006.01)
- (21) **International Application Number:**
PCT/US2006/011862
- (22) **International Filing Date:** 30 March 2006 (30.03.2006)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
60/667,887 1 April 2005 (01.04.2005) US
11/277,811 29 March 2006 (29.03.2006) US
- (71) **Applicant (for all designated States except US):**
BIONOVO, INC. [US/US]; Suite 375, 5858 Horton
Street, Emeryville, California 92608 (US).
- (72) **Inventor; and**
- (75) **Inventor/Applicant (for US only):** **COHEN, Isaac**
[US/US]; 361 La Salle Avenue, Piedmont, California
94610 (US).
- (74) **Agents:** **GRUMBLING, Matthew** et al.; Wilson Sonsini
Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali-
fornia 94304-1050 (US).
- (81) **Designated States (unless otherwise indicated, for every
kind of national protection available):** AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV,
LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) **Designated States (unless otherwise indicated, for every
kind of regional protection available):** ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- (88) **Date of publication of the international search report:**
31 December 2008



WO 2006/107745 A3

(54) **Title:** COMPOSITION FOR TREATMENT OF MENOPAUSE

(57) **Abstract:** A novel herbal extract, MF101, is effective in the treatment of symptoms of menopause.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/11862

A. CLASSIFICATION OF SUBJECT MATTER
 IPC: **A61K 49/00(2006.01),36/00(2006.01);A01N 65/00(2006.01)**

 USPC: 424/725,745,757,195.15, 764,773,776,777,775,774,9.2
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 424/725,745,757,195.15, 764,773,776,777,775,774,9.2

 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Bensky, D. et al. Chinese Herbal Medicine Medicine: Formulas & Strategies. 1990, Eastland Press, Inc., Seattle, Washington, pp 117, 224, 379, 380, 383 and 384.	1-24
A	Lee, T-K et al. Inhibitory Effects of Scutellaria barbarata D. Don on Human Uterine Leiomyoma Smooth Muscle Cell Proliferation through Cell Cycle Analysis, 2004. International Immunology. Vol. 4, pages 447-454.	1-24
A	Liu, C.-W. et al. Estrogen Receptor Assays of Scutellariae Barbatae Herba, Lithospermi Radix and Oldenlandiae Herba. Pharmaceutical Research. 1995, Vol. 12, Supplemental 9, page s126.	1-24
A	Albert, A. et al. Efficacy and Safety of Phytoestrogen Preparation Derived from Glycine max (L.) Merr in Climacteric Symptomatology: A Multicentric, Open, Prospective and Non-randomized Trial. Phytomedicine, 2002. Vol. 9, pages 85-92.	1-24

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:		
"A" document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed	"&"	document member of the same patent family

Date of the actual completion of the international search 09 June 2008 (09.06.2008)	Date of mailing of the international search report 30 OCT 2008
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201	Authorized officer Michele Flood <i>Michele Flood</i> Telephone No. 571-272-0960

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/11862

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: 25-29
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Please See Continuation Sheet

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
 2. As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of any additional fees.
 3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

 4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
- Remark on Protest**
- The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
 - The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
 - No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US06/11862

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Duffy, R. et al. Improved Cognitive Function in Postmenopausal Women After 12 Weeks of Consumption of a Soya Extract Containing Isoflavones. <i>Pharmacology, Biochemistry and Behavior</i> , 2003. Vol. 75, No. 3, pages 721-729.	1-24
A	Suthar, A. C. et al. Pharmacological Activities of Genistein, an Isoflavone from Soy (Glycine max): Part II- Anti-cholesterol Activity, Effects on Osteoporosis & Menopausal Symptoms. <i>Indian Journal of Experimental Biology</i> , 2001. Vol. 39, No. 6, pages 520-525.	1-24
A	Wang, P. et al. HDTIC-1 and HDTIC-2, Two Components Extracted from Astragali Radix, Delay Replicative Senescence of Human Diploid Fibroblasts. <i>Mechanisms of Aging and Development</i> , 2003. Vol. 124, pages 1025-1034.	1-24
A	Hsu, H.-Y. et al. <i>Oriental Materia Medica: A Concise Guide</i> . 1986. Keats Publishing Inc., USA, pages 119, 120, 144, 145, 272, 273, 524 and 525.	1-24
A	Xiao-fan, Z. et al. <i>Chinese Medicinal Teas: Simple, Proven Folk Formulas for Common Disease Promoting Health</i> , August 2004. Blue Poppy Press, Third Printing, USA, pages 122, 123, 253-255 and 263.	1-24
A	Lu, H. C. <i>Chinese Herbs with Common Foods: Recipes for Health and Healing</i> , 1997. Japan. Kodansha International Inc., pages 94, 115, 119 and 120.	1-24
A	US 2003/0190375 A1 (ERDEIMEIER et al) 09 October 2003 (09.10.2003)	1-24
A	US 2003/0170292 A1 (YONG et al.) 11 September 2003 (11.09.2003)	1-24
A	JP 2004155779 A (TAISHO PHARMACEUT CO LTD) 03 June 2004 (03.06.2004)	1-24
A	JP 2002029980 A (DAICEL CHEM IND LTD) 29 January 2002 (29.01.2002)	1-24
A	JP 2001122871 A (NIPPON KAYAKU KK) 08 May 2001 (08.05.2001)	1-24
A	KUIPER, G.G.J.M. et al. Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor Beta. <i>Endocrinology</i> , 1998. Vol. 139, No. 10, pages 4252-4263.	30

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US06/11862

Continuation of Box II Reason 2:

The recitation of the limitation “comparing the ability of the drug candidate to activate the ER α linked ERE and the ER β linked ERE, whereby a drug candidate that activates ER β linked ERE to a greater extent than ER β linked ERE is determined to be likely to be a drug for treatment of menopause” fails to reasonably provide a method of evaluating a drug candidate for use as a drug for treatment of menopause when considering the determination of the ability of the drug candidate to activate an ER α -linked ERE and an ER β -linked ERE, as set forth by the requirements of the claimed assay.